Is UFP Technologies (UFPT) Undervalued After Argus Lifted Its Price Target?

UFP Technologies, Inc. (UFPT) completed the acquisition of CI Medical Inc. on September 7, 2026. The company's stock has seen a 5-day change of 288.79 USD, a 1st Jan change of +0.79%, and a year-to-date change of +30.07%.

UFP Technologies (UFPT) reported record Q2 profits of $20.9M, up 21.4% YoY, with net sales of $174.0M, up 15.1%. Gross margin rose to 29.3%, but SG&A expenses increased 21.8%, raising concerns. CEO noted near-term margin pressure due to Dominican Republic operations. Hedge fund interest declined, and short interest is high at 19.26% of float.

UFP Technologies (UFPT) reported Q2 2026 net sales of $174 million, up 15.1%, with organic sales growth of 12.4%. Adjusted EPS rose 16.8% to $2.92 and gross margin increased to 29.3%. Adjusted EBITDA was $36.4 million. Management cited MedTech strength, low leverage under 1x, and an acquisition pipeline of 5 to 10 opportunities.

UFP Technologies (NASDAQ: UFPT) shares rose about 24% by 2 p.m. ET after the company reported strong Q2 results. UFP said sales grew 15%, adjusted EPS rose 17%, and revenue increased 15% to its five largest customers. The company also reported 12% organic growth and 20% growth in its core medtech unit, and is monitoring tuck-in acquisitions.

UFP Technologies (UFPT) shares rose 18.5% after the company reported Q2 2026 results that beat Wall Street. Revenue increased 15.1% to $174 million, adjusted EPS was $2.92 versus $2.56 expected, and adjusted EBITDA was $36.39 million, 11.5% above forecasts, according to the company.

UFP Technologies (NASDAQ:UFPT) reported Q2 CY2026 results. Revenue rose 15.1% year on year to $174 million, exceeding Wall Street estimates by 9.1% (per the article). Non-GAAP EPS was $2.92, up from $2.50 a year earlier, and 14.2% above consensus. The stock rose 5.3% to $281.50 after results.